HER2-Positive Gastric Adenocarcinoma — Trials

HER2-Positive Gastric Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

43 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 15
Recruiting: 6
Ph III recruiting: 2
Growth YoY: —
Industry share: 40%
Top sponsor: Qilu Hospital of Shandong University
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (7)

clinicaltrialsPublishedShowing 1–4 of 4 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06764875	A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer	recruiting	Phase 3	840	AstraZenecaINDUSTRY	28	Sep 11, 2026	clinicaltrials
NCT06532006	A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer	recruiting	Phase 3	550	Shanghai Henlius BiotechINDUSTRY	17	Feb 27, 2026